公开(公告)号：US20220280523A1

公开(公告)日：2022-09-08

申请号：US17644491

申请日：2021-12-15

Applicant: Novartis AG

Inventor： Giordano CAPONIGRO ,  Xizhong HUANG ,  Joseph LEHAR ,  Hui-Qin WANG

IPC: A61K31/53 ,  A61K45/06 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/5377

Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination.

公开(公告)号：US20230398115A1

公开(公告)日：2023-12-14

申请号：US18154717

申请日：2023-01-13

Applicant: Novartis AG

Inventor： Giordano CAPONIGRO ,  Ensar HALILOVIC ,  Thomas HORN-SPIROHN ,  Joseph LEHAR

IPC: A61K31/506 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5375 ,  A61P35/00 ,  A61K31/337 ,  A61K31/4184 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/635

CPC classification number: A61K31/506 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5375 ,  A61P35/00 ,  A61K31/337 ,  A61K31/4184 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/635

Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) an Mdm2 inhibitor and (b)(i) a MEK inhibitor and/or (b)(ii) Bcl2 inhibitor, particularly for use in the treatment of a cancer. This disclosure also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.

公开(公告)号：US20210260059A1

公开(公告)日：2021-08-26

申请号：US17188726

申请日：2021-03-01

Applicant: NOVARTIS AG

Inventor： Giordano CAPONIGRO ,  Ensar HALILOVIC ,  Thomas HORN-SPIROHN ,  Joseph LEHAR

IPC: A61K31/506 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5375 ,  A61P35/00 ,  A61K31/337 ,  A61K31/4184 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/635

Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) an Mdm2 inhibitor and (b)(i) a MEK inhibitor and/or (b)(ii) Bcl2 inhibitor, particularly for use in the treatment of a cancer. This disclosure also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.

公开(公告)号：US20210186973A1

公开(公告)日：2021-06-24

申请号：US17074120

申请日：2020-10-19

Applicant: NOVARTIS AG

Inventor： Giordano CAPONIGRO ,  Thomas HORN-SPIROHN ,  Joseph LEHAR

IPC: A61K31/519 ,  A61K31/4439 ,  A61K31/506 ,  A61P35/02

Abstract: The present disclosure relates to pharmaceutical combinations comprising a cyclin dependent kinase 4/6 (CDdK4/6) inhibitor compound, (b) a B-Raf inhibitor compound, and optionally (c) an aipha-isoform specific phosphatidylinositol 3-kinase (P13K) inhibitor compound, for the treatment or prevention of cancer, as well as related pharmaceutical compositions, uses, and methods of treatment or prevention of cancer.

公开(公告)号：US20180318275A1

公开(公告)日：2018-11-08

申请号：US15755797

申请日：2016-08-25

Applicant: Novartis AG

Inventor： Giordano CAPONIGRO ,  Thomas HORN-SPIROHN ,  Joseph LEHAR

IPC: A61K31/4439 ,  A61P35/00

CPC classification number: A61K31/4439 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00 ,  A61P35/00

Abstract: The present disclosure pertains to a pharmaceutical combination comprising (a) an alpha-isoform specific PI3K inhibitor, (b) an MDM2 inhibitor, and optionally (c) a BCL-2 inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer a subject in need thereof comprising administering a therapeutically effective amount of such combination.